CCX140-B | CAS# 1100318-47-5 | CCR2 Antagonist

MedKoo Cat#: 564126 | Name: CCX140-B

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CCX140-B is a potent CCR2 antagonist.

Chemical Structure

CCX140-B

CAS#1100318-47-5

Theoretical Analysis

MedKoo Cat#: 564126

Name: CCX140-B

CAS#: 1100318-47-5

Chemical Formula: C20H13ClF3N5O3S

Exact Mass: 495.0380

Molecular Weight: 495.86

Elemental Analysis: C, 48.45; H, 2.64; Cl, 7.15; F, 11.49; N, 14.12; O, 9.68; S, 6.47

Price and Availability

Size	Price	Availability	Quantity
100mg	USD 650.00	2 Weeks
250mg	USD 1,350.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

CCX140-B; CCX140B; CCX140 B; Ilacirnon

IUPAC/Chemical Name

4-Chloro-N-(5-methyl-2-(7H-pyrrolo[2,3-d]pyrimidine-4-carbonyl)pyridin-3-yl)-3-(trifluoromethyl)benzenesulfonamide

InChi Key

LUUMLYXKTPBTQR-UHFFFAOYSA-N

InChi Code

InChI=1S/C20H13ClF3N5O3S/c1-10-6-15(29-33(31,32)11-2-3-14(21)13(7-11)20(22,23)24)17(26-8-10)18(30)16-12-4-5-25-19(12)28-9-27-16/h2-9,29H,1H3,(H,25,27,28)

SMILES Code

O=S(C1=CC=C(Cl)C(C(F)(F)F)=C1)(NC2=CC(C)=CN=C2C(C3=C4C(NC=C4)=NC=N3)=O)=O

Appearance

Solid powder

Purity

>95% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 495.86 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Perez-Gomez MV, Sanchez-Niño MD, Sanz AB, Zheng B, Martín-Cleary C, Ruiz-Ortega M, Ortiz A, Fernandez-Fernandez B. Targeting inflammation in diabetic kidney disease: early clinical trials. Expert Opin Investig Drugs. 2016 Sep;25(9):1045-58. doi: 10.1080/13543784.2016.1196184. Epub 2016 Jun 13. Review. PubMed PMID: 27268955. 2: de Zeeuw D, Bekker P, Henkel E, Hasslacher C, Gouni-Berthold I, Mehling H, Potarca A, Tesar V, Heerspink HJ, Schall TJ; CCX140-B Diabetic Nephropathy Study Group. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. Lancet Diabetes Endocrinol. 2015 Sep;3(9):687-96. doi: 10.1016/S2213-8587(15)00261-2. Epub 2015 Aug 9. PubMed PMID: 26268910. 3: Sullivan T, Miao Z, Dairaghi DJ, Krasinski A, Wang Y, Zhao BN, Baumgart T, Ertl LS, Pennell A, Seitz L, Powers J, Zhao R, Ungashe S, Wei Z, Boring L, Tsou CL, Charo I, Berahovich RD, Schall TJ, Jaen JC. CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice. Am J Physiol Renal Physiol. 2013 Nov 1;305(9):F1288-97. doi: 10.1152/ajprenal.00316.2013. Epub 2013 Aug 28. PubMed PMID: 23986513; PubMed Central PMCID: PMC4073927. 4: Sullivan TJ, Miao Z, Zhao BN, Ertl LS, Wang Y, Krasinski A, Walters MJ, Powers JP, Dairaghi DJ, Baumgart T, Seitz LC, Berahovich RD, Schall TJ, Jaen JC. Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes. Metabolism. 2013 Nov;62(11):1623-32. doi: 10.1016/j.metabol.2013.06.008. Epub 2013 Aug 15. PubMed PMID: 23953944. 5: Sullivan TJ, Dairaghi DJ, Krasinski A, Miao Z, Wang Y, Zhao BN, Baumgart T, Berahovich R, Ertl LS, Pennell A, Seitz L, Miao S, Ungashe S, Wei Z, Johnson D, Boring L, Tsou CL, Charo IF, Bekker P, Schall TJ, Jaen JC. Characterization of CCX140-B, an orally bioavailable antagonist of the CCR2 chemokine receptor, for the treatment of type 2 diabetes and associated complications. J Pharmacol Exp Ther. 2012 Jun 5. doi: 10.1124/jpet.111.190918. Epub 2012 Jun 5. Retraction in: J Pharmacol Exp Ther. 2012 Jul;342(1):234. PubMed PMID: 22378937.